BCRX

9.67

2.76% 0.26

Dopo l'orario di chiusura: 9.67

Biocryst Pharmaceuticals Inc (BCRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCRX Giù? Forum Previsione

Precedente Chiudi:

$9.41

Aprire:

$9.39

Volume 24 ore:

3.71M

Relative Volume:

0.68

Capitalizzazione di mercato:

$2.43B

Reddito:

$874.84M

Utile/perdita netta:

$263.86M

Rapporto P/E:

8.0376

EPS:

1.2031

Flusso di cassa netto:

$327.41M

1 W Prestazione:

+0.83%

1M Prestazione:

+17.64%

6M Prestazione:

+50.62%

1 anno Prestazione:

+37.36%

Intervallo 1D:

$9.37

$9.68

Intervallo di 1 settimana:

$9.34

$9.98

Portata 52W:

$6.00

$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Nome

Biocryst Pharmaceuticals Inc

Settore

Healthcare (1110)

Industria

Drug Manufacturers - Specialty & Generic (83)

Telefono

919-859-1302

Indirizzo

4505 EMPEROR BOULEVARD, DURHAM, NC

Dipendente

435

Cinguettio

@biocrystpharma

Prossima data di guadagno

2025-02-24

Ultimi documenti SEC

BCRX's Discussions on Twitter

Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BCRX Biocryst Pharmaceuticals Inc	9.67	2.40B	874.84M	263.86M	327.41M	1.2031
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-18	Ripresa	Evercore ISI	Outperform
2025-10-15	Ripresa	TD Cowen	Buy
2025-10-01	Downgrade	Evercore ISI	Outperform → In-line
2025-04-29	Iniziato	Cantor Fitzgerald	Overweight
2025-02-25	Iniziato	Wedbush	Outperform
2023-11-20	Ripresa	JP Morgan	Overweight
2023-09-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Aggiornamento	Jefferies	Hold → Buy
2023-07-13	Aggiornamento	BofA Securities	Neutral → Buy
2023-02-22	Aggiornamento	Needham	Hold → Buy
2022-11-02	Aggiornamento	Evercore ISI	In-line → Outperform
2022-08-05	Downgrade	Evercore ISI	Outperform → In-line
2022-08-05	Downgrade	Oppenheimer	Outperform → Perform
2022-04-18	Downgrade	Barclays	Overweight → Equal Weight
2022-04-11	Downgrade	BofA Securities	Buy → Neutral
2021-12-10	Iniziato	Oppenheimer	Outperform
2021-08-06	Downgrade	Jefferies	Buy → Hold
2021-08-03	Iniziato	Cantor Fitzgerald	Overweight
2021-03-01	Iniziato	Cowen	Outperform
2020-09-29	Ripresa	JP Morgan	Overweight
2020-06-17	Iniziato	BTIG Research	Neutral
2020-05-05	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-15	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Ripresa	Piper Jaffray	Overweight
2018-08-08	Ripresa	JP Morgan	Overweight
2018-07-17	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-06-22	Iniziato	Seaport Global Securities	Neutral
2018-01-02	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Iniziato	Barclays	Equal Weight
2017-09-15	Iniziato	RBC Capital Mkts	Sector Perform
2017-09-06	Aggiornamento	JP Morgan	Neutral → Overweight
2017-09-06	Aggiornamento	Jefferies	Hold → Buy
2017-02-16	Iniziato	Ladenburg Thalmann	Buy
2016-08-12	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-08-04	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	FBR Capital	Outperform
2016-02-09	Downgrade	JP Morgan	Overweight → Neutral
2016-02-09	Downgrade	Needham	Buy → Hold

Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

Apr 14, 2026

Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones - Stock Traders Daily

Apr 14, 2026

Apr 13, 2026

BioCryst to File Peramivir NDA Supported by BARDA/HHS Funding - AOL.com

Apr 13, 2026

BCRX Should I Buy - Intellectia AI

Apr 13, 2026

BCRX.O Forecast — Price Prediction for 2026. Should I Buy BCRX.O? - Intellectia AI

Apr 13, 2026

BCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 13, 2026

BCRX.O PE Ratio & Valuation, Is BCRX.O Overvalued - Intellectia AI

Apr 13, 2026

Apr 12, 2026

Free cash flow per share of BioCryst Pharmaceuticals, Inc. – DUS:BO1 - TradingView — Track All Markets

Apr 12, 2026

BCRX PE Ratio & Valuation, Is BCRX Overvalued - Intellectia AI

Apr 12, 2026

Apr 10, 2026

BCRX Stock Price, Quote & Chart | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill

Apr 10, 2026

A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment - Sahm

Apr 09, 2026

Apr 08, 2026

R&D Leadership Shake-Up at BioCryst (BCRX) Could Be A Game Changer For Its Pipeline Strategy - Sahm

Apr 08, 2026

Apr 07, 2026

BioCryst (BCRX) Chief R&D Officer receives large stock option and RSU inducement grants - Stock Titan

Apr 07, 2026

Sandeep Menon of BIOCRYST PHARMACEUTICALS (BCRX) submits Form 3 - Stock Titan

Apr 07, 2026

RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating - Moomoo

Apr 07, 2026

New Strong Buy Stocks for June 25th - MSN

Apr 07, 2026

BioCryst (BCRX) soars 13% on acquisition buzz - MSN

Apr 07, 2026